TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report issued on Wednesday. The firm issued a hold rating on the stock.

TherapeuticsMD Trading Up 2.2 %

NASDAQ TXMD opened at $1.83 on Wednesday. TherapeuticsMD has a 1-year low of $1.43 and a 1-year high of $4.35. The company has a 50 day moving average of $1.91 and a 200-day moving average of $2.10.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Friday, May 10th. The company reported ($0.07) EPS for the quarter. The business had revenue of $0.31 million for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in TherapeuticsMD stock. ADAR1 Capital Management LLC acquired a new stake in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 272,160 shares of the company’s stock, valued at approximately $612,000. ADAR1 Capital Management LLC owned approximately 2.57% of TherapeuticsMD at the end of the most recent reporting period. Hedge funds and other institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.